Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of pirtobrutinib in previously treated CLL/SLL or NHL
2023-509270-37-00Phase 2Completed
- Sponsor
- Loxo Oncology
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) and 4 more (10 arms), sponsored by Loxo Oncology. Started Jun 2024; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2023-509270-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509270-37-00.